Published in Am J Pathol on January 17, 2008
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut (2014) 1.48
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis (2014) 1.35
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol (2009) 1.17
Isolated polycystic liver disease. Adv Chronic Kidney Dis (2010) 1.08
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology (2013) 1.03
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs (2010) 0.94
Polycystic liver diseases. Dig Liver Dis (2010) 0.93
Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression. Exp Biol Med (Maywood) (2009) 0.92
Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.88
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Recent advances on the mechanisms regulating cholangiocyte proliferation and the significance of the neuroendocrine regulation of cholangiocyte pathophysiology. Ann Transl Med (2013) 0.84
Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. Lab Invest (2016) 0.83
Expression and localization of growth hormone receptor in the oviduct of cyclic and pregnant pigs and mid-implantation conceptuses. Histochem Cell Biol (2009) 0.80
Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. Liver Int (2013) 0.80
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol (2014) 0.78
Pleuritic chest pain from portal hypertensive gastropathy in ESRD patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis. J Renal Inj Prev (2016) 0.75
Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging. Oncotarget (2016) 0.75
Role of sex hormones in the modulation of cholangiocyte function. World J Gastrointest Pathophysiol (2010) 0.75
Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet (2003) 13.33
Autosomal dominant polycystic kidney disease. N Engl J Med (1993) 5.64
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Intraflagellar transport and cilia-dependent diseases. Trends Cell Biol (2002) 2.67
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology (2006) 2.43
A physiological view of the primary cilium. Annu Rev Physiol (2005) 2.20
Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem (2000) 2.07
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Isolation and characterization of cholangiocyte primary cilia. Am J Physiol Gastrointest Liver Physiol (2006) 1.92
Primary cilia in normal and pathological tissues. Pathobiology (1995) 1.84
Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology (2003) 1.80
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology (1997) 1.45
New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol (2005) 1.40
Polycystic kidney disease--the ciliary connection. Lancet (2003) 1.37
Polycystins: polymodal receptor/ion-channel cellular sensors. Pflugers Arch (2005) 1.37
Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology (1990) 1.36
Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology (2000) 1.28
Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet (2000) 1.27
Molecular genetics and pathogenesis of autosomal dominant polycystic kidney disease. Annu Rev Med (2001) 1.27
Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology (2004) 1.24
Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol (2004) 1.24
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene (2003) 1.23
Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology (2004) 1.21
Molecular genetics and mechanism of autosomal dominant polycystic kidney disease. Mol Genet Metab (2000) 1.17
Insulin-like growth factor 1 is required for G2 progression in the estradiol-induced mitotic cycle. Proc Natl Acad Sci U S A (1999) 1.17
Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology (2002) 1.15
Polycystins, calcium signaling, and human diseases. Biochem Biophys Res Commun (2004) 1.14
The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol (2005) 1.12
Regulation of cholangiocyte proliferation. Liver (2001) 1.10
Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc (1990) 1.10
The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat (1999) 1.05
Regulation and deregulation of cholangiocyte proliferation. J Hepatol (2000) 1.02
Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology (1990) 1.01
Autosomal dominant polycystic kidney disease: molecular genetics and molecular pathogenesis. Hum Genet (2000) 1.01
Functional heterogeneity of cholangiocytes. Semin Liver Dis (2002) 1.00
The liver in autosomal dominant polycystic kidney disease. Implications for pathogenesis. Arch Pathol Lab Med (1990) 0.99
Effect of ovariectomy on the proliferative capacity of intrahepatic rat cholangiocytes. Gastroenterology (2002) 0.97
Activation of the IGF1 system characterizes cholangiocyte survival during progression of primary biliary cirrhosis. J Histochem Cytochem (2006) 0.97
The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone (2006) 0.96
Alfa and beta estrogen receptors and the biliary tree. Mol Cell Endocrinol (2002) 0.95
Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther (2003) 0.93
Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol (1992) 0.91
Activation of vascular endothelial growth factor (VEGF) by the ER-alpha variant, ERDelta3. Breast Cancer Res Treat (2006) 0.91
Continuous epithelial cell lines from ADPKD liver cysts exhibit characteristics of intrahepatic biliary epithelium. Am J Physiol (1995) 0.88
Insulin-like growth factor I in human gastrointestinal exocrine secretions. Regul Pept (1994) 0.88
Scanning electron microscopy demonstration of cilia in rat intrahepatic bile ducts. Anat Embryol (Berl) (1974) 0.87
Autosomal dominant polycystic kidney disease decreases anion exchanger activity. Am J Physiol (1997) 0.79
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology (2011) 2.37
Human hepatic stem cell and maturational liver lineage biology. Hepatology (2011) 1.99
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology (2011) 1.94
Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res (2010) 1.90
Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology (2006) 1.86
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology (2012) 1.81
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology (2002) 1.79
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol (2011) 1.74
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology (2013) 1.65
Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology (2009) 1.65
Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl (2008) 1.65
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology (2007) 1.59
Cholangiocarcinoma: update and future perspectives. Dig Liver Dis (2010) 1.58
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol (2008) 1.57
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat (2011) 1.51
Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. Dig Liver Dis (2010) 1.51
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
The biliary tree--a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol (2012) 1.50
Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds. Hepatology (2010) 1.48
Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of solid pancreatic masses. Clin Gastroenterol Hepatol (2010) 1.46
cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol (2004) 1.46
Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium. Lab Invest (2009) 1.45
Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int (2011) 1.45
Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut (2009) 1.44
Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem (2007) 1.43
"The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. J Hepatol (2011) 1.42
Evaluation of differential gene expression by microarray analysis in small and large cholangiocytes isolated from normal mice. Liver Int (2003) 1.42
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Dig Liver Dis (2009) 1.40
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol (2006) 1.40
Emerging roles of Notch signaling in liver disease. Hepatology (2014) 1.39
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology (2005) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol (2010) 1.36
Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med (2012) 1.35
Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med (2009) 1.32
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2002) 1.28
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect (2007) 1.25
Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology (2004) 1.24
Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol (2004) 1.24
H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest (2007) 1.24
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res (2005) 1.23
Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia. Hepatology (2011) 1.22
Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem (2008) 1.22
Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int (2009) 1.21
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology (2002) 1.20
Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol (2006) 1.20
Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem (2010) 1.19
Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19